Tazemetostat for Epithelioid Sarcoma
Study Summary
This trial is testing a new drug to treat a type of cancer called epithelioid sarcoma. The trial will have two parts and will compare the new drug to a placebo.
- Advanced Epithelioid Sarcoma
- Soft Tissue Sarcoma
Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 2 trial • 20 Patients • NCT03456726Awards & Highlights
Trial Design
Find a site
Who is running the clinical trial?
Media Library
Frequently Asked Questions
What is the desired patient population for this clinical trial?
"This clinical trial requires 164 individuals that fit the pre-determined inclusion criteria. Those interested in participating can do so at University of Michigan Medical Center located in Ann Arbor, Michigan or Sarah Cannon Research Institute at HealthONE in Denver, Colorado."
Could you please tell me what other scientific research studies have been conducted that involve Tazemetostat?
"The first trial for tazemetostat was completed in 1997 at Spectrum Health Hospital - Butterworth Campus. As of right now, there have been a total of 18941 completed trials worldwide. There are currently 399 live trials, with a large concentration in Ann Arbor, Michigan."
Is Tazemetostat a safe medication for people to take?
"Tazemetostat is rated as a 3 in terms of safety by our team at Power. This is because it is a Phase 3 trial, meaning that there is evidence from past trials to support both its efficacy and safety."
To your knowledge, are there other studies like this one?
"Tazemetostat has had 399 ongoing trials in 67 countries and 1972 cities since 1997. The original study, sponsored by Alfacell, was a Phase 3 drug approval trial that involved 300 patients. Since the completion of that trial, 18941 more have been completed."